Work

Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.3504

Authors: Howard S. Hochster, Paul J. Catalano, Peter J. O'Dwyer, Edith P. Mitchell, Deirdre Jill Cohen, Bryan Andrew Faller, Jeremy S. Kortmansky, Sheetal Mehta Kircher, Jill Lacy, Heinz-Josef Lenz, Udit N. Verma, Al Bowen Benson, ECOG-ACRIN

Institutions: Rutgers Cancer Institute, Dana-Farber Cancer Institute, Abramson Cancer Center, University of Pennsylvania, Thomas Jefferson University, Sidney Kimmel Cancer Center, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Yale University, Smilow Cancer Hospital, University of Southern California, The University of Texas Southwestern Medical Center, Northwestern Medicine

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891817128

Cites:

Cited by: 5

Related to: 10